[Long-term clinical effect of maxacalcitol on hemodialysis patients with secondary hyperparathyroidism].

@article{Akizawa2002LongtermCE,
  title={[Long-term clinical effect of maxacalcitol on hemodialysis patients with secondary hyperparathyroidism].},
  author={Tadao Akizawa and Kaneyuki Kurokawa},
  journal={Clinical calcium},
  year={2002},
  volume={12 6},
  pages={
          781-8
        }
}
A trial on the long-term administration of 22-oxacalcitriol (maxacalcitol, OCT) was conducted among 124 patients with chronic renal failure on maintenance hemodialysis (HD) complicated with secondary hyperparathyroidism (2 degrees HPT ). In the trial, OCT was administered 3 times weekly for 26 weeks subsequent to a 26-week pre-trial. As a result, intact-parathyroid hormone (PTH) levels fell significantly after the start of administration and were well controlled for one year. The levels of… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…